SCHEMBL20190080

SCHEMBL20190080

COc1cc(OC(F)(F)F)ccc1-c1ccn2ncc(C(F)(F)F)c2n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 5/20 0.65
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
ALDH1A1 P00352 1/20 0.39
CRHR1 P34998 3/20 0.38
PIM1 P11309 2/20 0.38
PIM2 Q9P1W9 2/20 0.38
RUNX1 Q01196 1/20 0.36
TLR9 Q9NR96 1/20 0.36
PRKCA P17252 1/20 0.36
PRKCI P41743 1/20 0.36
PRKCE Q02156 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20191052 0.87 SCN5A (0.50) SCN5AMAPTSMN1; SMN2MEN1NPC1
SCHEMBL20189286 0.87 SCN5A (0.67) SCN5APIM1PIM2MAOAMAOB
SCHEMBL20190843 0.84 SCN5A (0.61) SCN5APIM1PIM2MAOAMAOB
SCHEMBL20190635 0.79 SCN5A (0.67) SCN5APIM1PIM2
SCHEMBL20208586 0.79 SCN5A (1.00) SCN5AMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL20190634 0.79 SCN5A (0.62) SCN5ACRHR1TLR9MAOAMAOB
SCHEMBL20190817 0.75 TLR9 (0.41) SCN5ACRHR1TLR9MAOAMAOB
SCHEMBL20189530 0.73 SCN5A (0.67) SCN5AMAPTSMN1; SMN2MEN1NPC1
SCHEMBL20190776 0.73 SCN5A (0.58) SCN5APIM1PIM2MAOAMAOB
SCHEMBL20190458 0.72 CYP1A2 (0.48) SCN5AMAPTSMN1; SMN2MEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210188839-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2021-06-24 US disclosed
US-20210188839-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2021-06-24 US disclosed
WO-2018098500-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2018-05-31 WO disclosed
WO-2018098500-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188839-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B SCN5A 8/4885MAPT 670/4885SMN1; SMN2 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.